The trajectory of copyright's flagship drug presents a nuanced case for observers in the medicinal sector. While initially a tremendous success, producing huge profits, the exclusivity lapse and the subsequent arrival of generic competitors have drastically impacted revenue. This poses questions about the ongoing profitability of similar therape… Read More